80wk Downtrend — falling+below (sma 3.58 vs px 1.74)
200wk Downtrend — falling+below (sma 4.70 vs px 1.74)
Short Attack — velZ +13.44 · age 28w×0.98 · 2.10%
RS Breakdown — momZ +0.21 · low 2w×1.00 · vs industry
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as … Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: February 12, 2019
Headquarters: Building C, Tel Aviv-Yafo, Israel, 6158101
Founder-Led: Yes — Adi Mor (Chief Executive Officer)
Key Metrics
Current Price
$1.74
Market Cap
$13.4M
Float
6.4M
Shares Outstanding
7.3M
P/E (Forward)
12.94
vs. Analyst Target
+762.1% to analyst PT
Dividend Rate
None
Analyst Target Price
$15.00 (2 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
N/A
-$6.0M
-$79,999
-$5.9M
2021
N/A
-$12.5M
-$34,023
-$12.3M
2022
N/A
-$27.6M
-$57,773
-$28.5M
2023
N/A
-$24.2M
-$66,827
-$25.4M
2024
N/A
-$13.9M
-$53,251
-$14.0M
2025
N/A
-$9.0M
-$70,555
-$9.5M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
N/A
-$2.1M
Sep 2025
N/A
-$1.7M
Dec 2025
N/A
-$1.9M
Mar 2026
N/A
-$1.8M
Ownership & Float
Insider Ownership
11.1%
Institutional Ownership
4.8%
Short Float
2.1%
% of All Funds Holding
0.17%
Number of Funds Holding
14
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$1.80
Near-term / short-term trend
Weekly
40-Week SMA
$1.99
Medium-term trend
Weekly
80-Week SMA
$3.58
Cyclical trend (business cycle)
Weekly
200-Week SMA
$4.70
Secular trend (multi-year)
Monthly
10-Month SMA
$1.91
Near-term monthly trend
Monthly
20-Month SMA
$3.55
Medium-term monthly trend
Monthly
40-Month SMA
$3.99
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$2.60
resistance
1.26x
6 months ago
$4.20
resistance
1.84x
10 months ago
Historical Earnings Reactions (30 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-0.47%
-0.06%
43.33%
10.81%
-34.64%
1 Day
-0.56%
-1.75%
36.67%
24.20%
-18.97%
1 Week
-1.81%
-0.46%
40.00%
60.66%
-41.20%
2 Weeks
-1.20%
-0.57%
50.00%
55.33%
-59.82%
1 Month
-2.15%
-9.42%
37.93%
60.28%
-50.93%
Next earnings: August 13, 2026 (31 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-3.7%
42.9%
7
Feb
3.1%
42.9%
7
Mar
-12.7%
37.5%
8
Apr
-3.9%
37.5%
8
May
7.3%
50.0%
8
Jun
-2.5%
37.5%
8
Jul
-10.8%
14.3%
7
Aug
1.8%
42.9%
7
Sep
-13.8%
14.3%
7
Oct
-3.6%
42.9%
7
Nov
-5.0%
42.9%
7
Dec
-0.9%
28.6%
7
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.37%
42.2%
348
Tuesday
0.37%
42.4%
384
Wednesday
0.02%
42.8%
381
Thursday
-0.14%
38.1%
373
Friday
-0.14%
43.7%
371
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 4.8%
Insider Transactions — Smart Summary
Total insider ownership: 11.1%
Founder-led management: Adi Mor (Chief Executive Officer)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Chemomab Therapeutics Ltd DRC
(CMMB) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.